CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.
3 Magnificent Stocks That Could Double or More by 2030
When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Annual Needham Virtual Healthcare Conference Call April 8, 2025 12:45 PM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Gil Blum - Needham & Company Gil Blum Good afternoon, everyone, and thank you for joining me at the second day of the Needham Healthcare conference. My name is Gil Blum, and I am senior biotech analyst here at Needham & Company with a focus on immune-oncology.
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Shares of biotechnology stocks such as Recursion Pharmaceuticals (RXRX -8.18%), Summit Therapeutics (SMMT -4.28%), and CRISPR Therapeutics AG (CRSP -8.06%) plunged on Monday, down 9.4%, 5.6%, and 9.2%, respectively, as of 12:55 p.m. ET.
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
CRISPR Therapeutics Set To Reach Previous Heights
Despite a lackluster launch, CASGEVY has significant potential in international markets, bolstering CRISPR's long-term value. Upcoming milestones and updates on CRISPR Therapeutics is currently sitting at historical support, at a valuation that is clinical assets are expected to drive shareholder value back to previous highs. We are bullish on CRISPR, rating it a buy with a $70 price target, as the stock currently sits at a strong support level of $40.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 Beaten-Down Stocks to Buy on the Dip
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics (CRSP 0.12%) and Merck (MRK -1.37%), two companies that develop innovative medical therapies.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $41.22, indicating a +0.12% shift from the previous trading day.
